Compare Abbott Laboratories (ABT) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs CubeSmart — how do they compare? Abbott Laboratories trades at $95.7 (market cap $166.94B), while CubeSmart trades at $40.1 (market cap $9.26B). The key difference: Abbott Laboratories is far larger — about 18× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.19%). Which is the better fit depends on your goals.
| ABT | CUBE | |
|---|---|---|
Market Cap | $166.94B | $9.26B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $42.60 |
52-Week Low | $82.57 | $35.36 |
Enterprise Value | $193.69B | $12.75B |
Dividend Yield | 2.63% | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CubeSmart (CUBE) trades at $40.88, down 0.24% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.63, beating expectations, and maintains strong profitability with a 28.93% net income margin. Recent news highlights the upcoming Q2 2026 earnings release on July 30, 2026, and a declared dividend of $0.53 per share.
Outlook is balanced with a consensus price target of $43.17 suggesting modest upside, but risks include a high debt load and interest rate sensitivity. The stock offers a solid dividend yield, yet faces headwinds from macroeconomic uncertainty and competitive pressures in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
